Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise Therapy | 4 | 2024 | 290 | 1.270 |
Why?
|
| Deglutition Disorders | 3 | 2024 | 488 | 1.160 |
Why?
|
| Ovarian Neoplasms | 10 | 2021 | 4774 | 1.060 |
Why?
|
| Patient Compliance | 2 | 2024 | 686 | 1.020 |
Why?
|
| Deglutition | 4 | 2024 | 187 | 0.870 |
Why?
|
| Uterine Cervical Dysplasia | 5 | 2012 | 222 | 0.800 |
Why?
|
| Survivors | 7 | 2021 | 1024 | 0.710 |
Why?
|
| Cancer Survivors | 3 | 2022 | 740 | 0.700 |
Why?
|
| Depression | 5 | 2020 | 1736 | 0.590 |
Why?
|
| Colposcopy | 6 | 2012 | 75 | 0.540 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2017 | 523 | 0.530 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2012 | 1913 | 0.530 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2016 | 1157 | 0.520 |
Why?
|
| Endpoint Determination | 1 | 2016 | 182 | 0.500 |
Why?
|
| Depressive Disorder | 2 | 2017 | 566 | 0.490 |
Why?
|
| Spectrum Analysis | 3 | 2012 | 144 | 0.490 |
Why?
|
| Testicular Neoplasms | 2 | 2010 | 554 | 0.470 |
Why?
|
| Health Behavior | 2 | 2010 | 597 | 0.460 |
Why?
|
| Medication Adherence | 1 | 2019 | 519 | 0.460 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 905 | 0.450 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 853 | 0.450 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2010 | 1228 | 0.370 |
Why?
|
| Life Style | 3 | 2017 | 614 | 0.350 |
Why?
|
| Pharyngeal Neoplasms | 2 | 2024 | 140 | 0.330 |
Why?
|
| Attitude to Death | 1 | 2009 | 102 | 0.320 |
Why?
|
| Anxiety | 2 | 2009 | 1235 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 2670 | 0.290 |
Why?
|
| Biomedical Technology | 1 | 2007 | 40 | 0.290 |
Why?
|
| Motivation | 2 | 2009 | 509 | 0.280 |
Why?
|
| Papanicolaou Test | 3 | 2007 | 130 | 0.260 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 919 | 0.250 |
Why?
|
| Vaginal Smears | 3 | 2007 | 183 | 0.250 |
Why?
|
| Spectrometry, Fluorescence | 4 | 2012 | 207 | 0.250 |
Why?
|
| Female | 30 | 2024 | 148509 | 0.240 |
Why?
|
| Head and Neck Neoplasms | 4 | 2024 | 4124 | 0.240 |
Why?
|
| Middle Aged | 22 | 2024 | 90021 | 0.240 |
Why?
|
| Patient Health Questionnaire | 2 | 2020 | 19 | 0.230 |
Why?
|
| Depressive Disorder, Major | 2 | 2020 | 426 | 0.220 |
Why?
|
| Adult | 21 | 2024 | 81555 | 0.220 |
Why?
|
| Breast Neoplasms | 5 | 2021 | 16186 | 0.210 |
Why?
|
| Self-Management | 1 | 2024 | 100 | 0.210 |
Why?
|
| Patient Satisfaction | 4 | 2012 | 917 | 0.200 |
Why?
|
| Aged | 17 | 2024 | 73161 | 0.200 |
Why?
|
| Mass Screening | 4 | 2020 | 1554 | 0.200 |
Why?
|
| Humans | 35 | 2024 | 270947 | 0.190 |
Why?
|
| Laryngeal Neoplasms | 1 | 2024 | 532 | 0.180 |
Why?
|
| Stress, Psychological | 2 | 2004 | 1043 | 0.180 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 2280 | 0.180 |
Why?
|
| Quality of Life | 6 | 2021 | 4732 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 5568 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 3972 | 0.170 |
Why?
|
| Surveys and Questionnaires | 6 | 2019 | 5904 | 0.160 |
Why?
|
| Graphite | 1 | 2018 | 18 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2021 | 623 | 0.160 |
Why?
|
| Comorbidity | 2 | 2016 | 2430 | 0.150 |
Why?
|
| Cross-Sectional Studies | 5 | 2017 | 4505 | 0.150 |
Why?
|
| Electromyography | 1 | 2018 | 232 | 0.150 |
Why?
|
| Health Care Surveys | 1 | 2019 | 423 | 0.150 |
Why?
|
| Risk Factors | 6 | 2016 | 17824 | 0.150 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 785 | 0.140 |
Why?
|
| Interviews as Topic | 2 | 2020 | 516 | 0.140 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 30941 | 0.140 |
Why?
|
| Radiation Injuries | 1 | 2024 | 1472 | 0.140 |
Why?
|
| Metal Nanoparticles | 1 | 2018 | 160 | 0.140 |
Why?
|
| Sertraline | 1 | 2016 | 42 | 0.130 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2016 | 62 | 0.130 |
Why?
|
| Blood Pressure | 1 | 2001 | 1594 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2019 | 1620 | 0.120 |
Why?
|
| Serotonin | 1 | 2016 | 293 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 536 | 0.120 |
Why?
|
| Remote Sensing Technology | 1 | 2013 | 12 | 0.120 |
Why?
|
| Smoking | 2 | 2016 | 2425 | 0.120 |
Why?
|
| Time Factors | 4 | 2019 | 13112 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 852 | 0.110 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 13976 | 0.110 |
Why?
|
| Dehydration | 1 | 2013 | 90 | 0.110 |
Why?
|
| Computers, Handheld | 1 | 2013 | 61 | 0.110 |
Why?
|
| Alphapapillomavirus | 2 | 2012 | 174 | 0.110 |
Why?
|
| Male | 11 | 2024 | 128454 | 0.110 |
Why?
|
| Papillomaviridae | 1 | 2016 | 642 | 0.100 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 1323 | 0.100 |
Why?
|
| Young Adult | 5 | 2020 | 22059 | 0.100 |
Why?
|
| Hypertension | 1 | 2001 | 1613 | 0.100 |
Why?
|
| Social Support | 2 | 2017 | 585 | 0.100 |
Why?
|
| Family Practice | 1 | 2012 | 132 | 0.100 |
Why?
|
| Eating | 1 | 2013 | 449 | 0.090 |
Why?
|
| Focus Groups | 1 | 2012 | 283 | 0.090 |
Why?
|
| Internal Medicine | 1 | 2012 | 161 | 0.090 |
Why?
|
| Exercise | 3 | 2021 | 1211 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4331 | 0.090 |
Why?
|
| United States | 5 | 2019 | 15983 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2016 | 2288 | 0.080 |
Why?
|
| Gynecology | 1 | 2012 | 232 | 0.080 |
Why?
|
| Pain | 2 | 2008 | 1696 | 0.080 |
Why?
|
| Self Report | 1 | 2013 | 792 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 6248 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 3862 | 0.080 |
Why?
|
| Logistic Models | 2 | 2010 | 3437 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 222 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2017 | 10349 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 5086 | 0.080 |
Why?
|
| Affective Symptoms | 1 | 2008 | 89 | 0.080 |
Why?
|
| Fruit | 1 | 2010 | 301 | 0.080 |
Why?
|
| Fear | 1 | 2009 | 260 | 0.080 |
Why?
|
| Nigeria | 1 | 2007 | 87 | 0.070 |
Why?
|
| Vegetables | 1 | 2010 | 330 | 0.070 |
Why?
|
| Prevalence | 3 | 2020 | 3420 | 0.070 |
Why?
|
| Recurrence | 1 | 2016 | 4881 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 1009 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2013 | 15253 | 0.070 |
Why?
|
| Cholesterol | 1 | 2010 | 678 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 592 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2013 | 1858 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 9043 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2016 | 13352 | 0.060 |
Why?
|
| Developing Countries | 1 | 2007 | 338 | 0.060 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 2984 | 0.060 |
Why?
|
| Ethnology | 1 | 2004 | 3 | 0.060 |
Why?
|
| Motor Activity | 1 | 2008 | 718 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2013 | 9307 | 0.060 |
Why?
|
| Prognosis | 4 | 2019 | 22458 | 0.060 |
Why?
|
| Marital Status | 1 | 2004 | 93 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2009 | 1287 | 0.060 |
Why?
|
| Education | 1 | 2004 | 124 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2016 | 6837 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2007 | 2851 | 0.060 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2004 | 73 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2006 | 439 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2007 | 804 | 0.050 |
Why?
|
| ROC Curve | 2 | 2020 | 1221 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2022 | 2346 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 5188 | 0.050 |
Why?
|
| Diet | 1 | 2010 | 1485 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2004 | 320 | 0.050 |
Why?
|
| Technology | 1 | 2022 | 103 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 750 | 0.050 |
Why?
|
| Patients | 1 | 2003 | 247 | 0.050 |
Why?
|
| Medically Underserved Area | 1 | 2021 | 123 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2013 | 9433 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2010 | 6027 | 0.040 |
Why?
|
| Age Factors | 1 | 2009 | 5496 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2020 | 219 | 0.040 |
Why?
|
| Palladium | 1 | 2018 | 56 | 0.040 |
Why?
|
| Disease Progression | 1 | 2009 | 6893 | 0.040 |
Why?
|
| Palliative Care | 1 | 2009 | 2154 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 5186 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2016 | 33827 | 0.040 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2016 | 14 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 1044 | 0.030 |
Why?
|
| Machine Learning | 1 | 2018 | 357 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2016 | 685 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 6172 | 0.030 |
Why?
|
| Health Status | 2 | 2008 | 627 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2013 | 39694 | 0.030 |
Why?
|
| Algorithms | 2 | 2018 | 3910 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 2289 | 0.030 |
Why?
|
| Psychometrics | 1 | 2017 | 963 | 0.030 |
Why?
|
| Microscopy, Interference | 1 | 2011 | 16 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 10250 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 14679 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 2465 | 0.020 |
Why?
|
| Internet | 1 | 2013 | 698 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2016 | 4360 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 1206 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 3920 | 0.020 |
Why?
|
| Exercise Test | 1 | 2006 | 315 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 2029 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2004 | 169 | 0.010 |
Why?
|
| Walking | 1 | 2006 | 274 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2006 | 613 | 0.010 |
Why?
|
| Lymphedema | 1 | 2006 | 239 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2006 | 557 | 0.010 |
Why?
|
| Body Composition | 1 | 2006 | 609 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2009 | 1548 | 0.010 |
Why?
|
| Educational Status | 1 | 2004 | 390 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2008 | 1005 | 0.010 |
Why?
|
| Self Concept | 1 | 2004 | 199 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 733 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 875 | 0.010 |
Why?
|
| Fatigue | 1 | 2008 | 1277 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 14864 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 9078 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2004 | 1257 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 2314 | 0.010 |
Why?
|
| Decision Making | 1 | 2007 | 1244 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 32577 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2006 | 2237 | 0.010 |
Why?
|
| Biopsy | 1 | 2003 | 3545 | 0.010 |
Why?
|
| Texas | 1 | 2006 | 6415 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 4983 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 62771 | 0.010 |
Why?
|